HBVtech, awarded an MBIA Commercialization Grant

HBVtech, awarded an MBIA Commercialization Grant

HBVtech, located in Frederick, MD, is a biopharma startup developing a novel chronic Hepatitis B cure drug that only requires a single injection. HBVtech has established proof of three concepts for this new treatment strategy and drug and is preparing for IND (Investigational New Drug) studies. This new drug was selected as one of the Hepatitis B drug cure candidates by NIH.

Comments are closed.